Drug Trial Radar · NCT07933133
A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosis
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Apr 1, 2029
Study completion Feb 1, 2030
Sponsor
- Lead sponsor
- CSPC-NBP Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, blinded, placebo- and active-controlled Phase II study to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of SYH9061 at different doses and dosing frequencies in patients with IPF, and to determine the optimal recommended dose for Phase III confirmatory studies.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
SYH9061Drug
Administered at the dose specified in the protocol.
PlaceboDrug
Administered at the dose specified in the protocol.
Ofev®Drug
Administered at the dose specified in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in FVC from baseline (mL)Time frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.